Literature DB >> 23945141

Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts.

Linda Scobie1, Vered Padler-Karavani, Stephanie Le Bas-Bernardet, Claire Crossan, Josef Blaha, Magda Matouskova, Ralph D Hector, Emanuele Cozzi, Bernard Vanhove, Beatrice Charreau, Gilles Blancho, Ludovic Bourdais, Mariachiara Tallacchini, Juan M Ribes, Hai Yu, Xi Chen, Jitka Kracikova, Ludomir Broz, Jiri Hejnar, Pavel Vesely, Yasuhiro Takeuchi, Ajit Varki, Jean-Paul Soulillou.   

Abstract

Acellular materials of xenogenic origin are used worldwide as xenografts, and phase I trials of viable pig pancreatic islets are currently being performed. However, limited information is available on transmission of porcine endogenous retrovirus (PERV) after xenotransplantation and on the long-term immune response of recipients to xenoantigens. We analyzed the blood of burn patients who had received living pig-skin dressings for up to 8 wk for the presence of PERV as well as for the level and nature of their long term (maximum, 34 y) immune response against pig Ags. Although no evidence of PERV genomic material or anti-PERV Ab response was found, we observed a moderate increase in anti-αGal Abs and a high and sustained anti-non-αGal IgG response in those patients. Abs against the nonhuman sialic acid Neu5Gc constituted the anti-non-αGal response with the recognition pattern on a sialoglycan array differing from that of burn patients treated without pig skin. These data suggest that anti-Neu5Gc Abs represent a barrier for long-term acceptance of porcine xenografts. Because anti-Neu5Gc Abs can promote chronic inflammation, the long-term safety of living and acellular pig tissue implants in recipients warrants further evaluation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23945141      PMCID: PMC3782708          DOI: 10.4049/jimmunol.1301195

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets.

Authors:  R Valdes-Gonzalez; A L Rodriguez-Ventura; D J G White; E Bracho-Blanchet; A Castillo; B Ramírez-González; M G López-Santos; B H León-Mancilla; L M Dorantes
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

2.  Long life with or without PERV.

Authors:  Yasuhiro Takeuchi; Jay Fishman
Journal:  Xenotransplantation       Date:  2010 Nov-Dec       Impact factor: 3.907

3.  International human xenotransplantation inventory.

Authors:  Antonino Sgroi; Leo H Bühler; Philippe Morel; Megan Sykes; Luc Noel
Journal:  Transplantation       Date:  2010-09-27       Impact factor: 4.939

4.  Colloquium paper: uniquely human evolution of sialic acid genetics and biology.

Authors:  Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-05       Impact factor: 11.205

5.  New biological temporary skin cover Xe-Derma(®) in the treatment of superficial scald burns in children.

Authors:  Robert Zajicek; Eva Matouskova; Ludomir Broz; Richard Kubok; Petr Waldauf; Radana Königova
Journal:  Burns       Date:  2010-11-02       Impact factor: 2.744

6.  No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation.

Authors:  Rafael Valdes-Gonzalez; Luis M Dorantes; Eduardo Bracho-Blanchet; Ana Rodríguez-Ventura; D J G White
Journal:  J Med Virol       Date:  2010-02       Impact factor: 2.327

7.  Long-term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell-based Academic Medical Center bioartificial liver.

Authors:  Giuseppe Di Nicuolo; Alba D'Alessandro; Barbara Andria; Vincenzo Scuderi; Michele Scognamiglio; Angela Tammaro; Antonio Mancini; Santolo Cozzolino; Ernesto Di Florio; Adele Bracco; Fulvio Calise; Robert A F M Chamuleau
Journal:  Xenotransplantation       Date:  2010 Nov-Dec       Impact factor: 3.907

8.  Activation of B cells by antigens on follicular dendritic cells.

Authors:  Mohey Eldin M El Shikh; Rania M El Sayed; Selvakumar Sukumar; Andras K Szakal; John G Tew
Journal:  Trends Immunol       Date:  2010-04-24       Impact factor: 16.687

9.  The viability change of pigskin in vitro.

Authors:  Liangpeng Ge; Lihua Sun; Junyin Chen; Xiuli Mao; Yong Kong; Fei Xiong; Jun Wu; Hong Wei
Journal:  Burns       Date:  2010-06       Impact factor: 2.744

Review 10.  Mechanisms that determine plasma cell lifespan and the duration of humoral immunity.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

View more
  50 in total

Review 1.  Regulation of Clinical Xenotransplantation-Time for a Reappraisal.

Authors:  David K C Cooper; Richard N Pierson; Bernhard J Hering; Muhammad M Mohiuddin; Jay A Fishman; Joachim Denner; Curie Ahn; Agnes M Azimzadeh; Leo H Buhler; Peter J Cowan; Wayne J Hawthorne; Takaaki Kobayashi; David H Sachs
Journal:  Transplantation       Date:  2017-08       Impact factor: 4.939

2.  Long-term safety from transmission of porcine endogenous retrovirus after pig-to-non-human primate corneal transplantation.

Authors:  Hyuk Jin Choi; Jiyeon Kim; Jae Young Kim; Hyun Ju Lee; Won Ryang Wee; Mee Kum Kim; Eung Soo Hwang
Journal:  Xenotransplantation       Date:  2017-05-14       Impact factor: 3.907

Review 3.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

4.  Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs.

Authors:  C Burlak; L L Paris; A J Lutz; R A Sidner; J Estrada; P Li; M Tector; A J Tector
Journal:  Am J Transplant       Date:  2014-06-06       Impact factor: 8.086

5.  Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation.

Authors:  Se Hyun Choi; Chang Ho Yoon; Hyun Ju Lee; Hong Pyo Kim; Jong Min Kim; Jeong-Hwan Che; Kyoung Min Roh; Hyuk Jin Choi; Jiyeon Kim; Eung Soo Hwang; Chung-Gyu Park; Mee Kum Kim
Journal:  Xenotransplantation       Date:  2018-07       Impact factor: 3.907

6.  Decellularization of fibroblast cell sheets for natural extracellular matrix scaffold preparation.

Authors:  Qi Xing; Keegan Yates; Mitchell Tahtinen; Emily Shearier; Zichen Qian; Feng Zhao
Journal:  Tissue Eng Part C Methods       Date:  2015-01       Impact factor: 3.056

7.  Screening pigs for xenotransplantation: expression of porcine endogenous retroviruses in transgenic pig skin.

Authors:  Magdalena Kimsa-Dudek; Barbara Strzalka-Mrozik; Malgorzata W Kimsa; Irena Blecharz; Joanna Gola; Bartlomiej Skowronek; Adrian Janiszewski; Daniel Lipinski; Joanna Zeyland; Marlena Szalata; Ryszard Slomski; Urszula Mazurek
Journal:  Transgenic Res       Date:  2015-03-27       Impact factor: 2.788

8.  Carbohydrate antigen expression and anti-pig antibodies in New World capuchin monkeys: Relevance to studies of xenotransplantation.

Authors:  Qi Li; Sahar Shaikh; Hayato Iwase; Cassandra Long; Whayoung Lee; Zhongqiang Zhang; Yi Wang; David Ayares; David K C Cooper; Hidetaka Hara
Journal:  Xenotransplantation       Date:  2019-02-16       Impact factor: 3.907

9.  Development of a consensus protocol to quantify primate anti-non-Gal xenoreactive antibodies using pig aortic endothelial cells.

Authors:  Agnes M Azimzadeh; Guerard W Byrne; Mohamed Ezzelarab; Emily Welty; Gheorghe Braileanu; Xiangfei Cheng; Simon C Robson; Christopher G A McGregor; David K C Cooper; Richard N Pierson
Journal:  Xenotransplantation       Date:  2014-09-01       Impact factor: 3.907

10.  Characterization of immunogenic Neu5Gc in bioprosthetic heart valves.

Authors:  Eliran Moshe Reuven; Shani Leviatan Ben-Arye; Tal Marshanski; Michael E Breimer; Hai Yu; Imen Fellah-Hebia; Jean-Christian Roussel; Cristina Costa; Manuel Galiñanes; Rafael Mañez; Thierry Le Tourneau; Jean-Paul Soulillou; Emanuele Cozzi; Xi Chen; Vered Padler-Karavani
Journal:  Xenotransplantation       Date:  2016-09-09       Impact factor: 3.907

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.